top of page
Search

The “Sex Peptide” Everyone Is Talking About — Does It Actually Work? A Sex Therapist’s Honest Take (Including Her Own Experience)

  • Writer: Holly Wood
    Holly Wood
  • 3 hours ago
  • 10 min read
Couple excitedly looking at their phone while exploring a prescription libido treatment together, highlighting conversations about sexual desire and evidence-based care often discussed in sex therapy and relationship counseling in Orange County.
Can a libido injection really reignite desire? The science is more nuanced than the hype.

If you spend any time in wellness circles, peptide biohacking communities, or even just scrolling TikTok, you’ve probably heard whispers about PT-141 — the peptide that supposedly turns desire back on like a light switch. The claims are seductive: inject a little bremelanotide before a date night, and suddenly you’re a different person. Your libido is back. You’re in the mood. Problem solved.


As a sex and relationship therapist, I am professionally obligated to follow the evidence. And as a curious human who has also personally tried this peptide four times, I have some thoughts. Spoiler: the truth is much more interesting — and more nuanced — than the hype.


In this post, we’re going to dig into what PT-141 actually is, what the research really says, the critical difference between arousal and desire (this is the heart of everything), and why flooding your body with “arousal juice” may not do much if all of the brakes are still firmly engaged. I’ll also share my own experience — including the nausea that almost made me swear off the whole thing entirely.


And if you’d rather watch than read, feel free to check out my YouTube video on this topic!


What Is PT-141 (Bremelanotide / Vyleesi)?


Hand holding a Vyleesi (bremelanotide) injector, representing evidence-based discussions about low sexual desire and treatment options in sex therapy and relationship counseling in Orange County.
Understanding how a treatment works is just as important as knowing what it's marketed to do.

PT-141, generically known as bremelanotide and sold under the brand name Vyleesi, is a synthetic peptide that works on the central nervous system rather than the genitals. This is what makes it fundamentally different from drugs like Viagra or Cialis, which work by increasing blood flow to genital tissue.


Bremelanotide is a melanocortin receptor agonist — it binds to melanocortin receptors (particularly MC3R and MC4R) in the brain and is thought to activate pathways involved in sexual motivation and arousal (Kingsberg et al., 2019). In plain language: it works upstairs, in the brain’s reward and motivation systems, rather than downstairs.


It was FDA-approved in 2019 under a very specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That’s an important qualifier we’ll come back to. It is administered as a subcutaneous injection (under the skin, typically in the abdomen or thigh) about 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than eight times per month (Treatment of Hypoactive Sexual Desire Disorder Among Women, 2021).


A Brief History


Originally developed as a tanning agent, researchers noticed that participants in early trials were experiencing unexpected side effects — including spontaneous erections and increased sexual interest. This serendipitous discovery pivoted the compound toward sexual medicine research, eventually leading to the FDA approval of Vyleesi for HSDD (Novel Emerging Therapies for Erectile Dysfunction, 2020).



Arousal vs. Desire: Why This Distinction Matters More Than Anything


Couple sharing a kiss in bed, illustrating the connection between intimacy, desire, and arousal often explored through sex therapy and relationship counseling in Orange County.
Desire grows where emotional connection and physical arousal have room to meet.

Before we can evaluate PT-141 fairly, we need to establish something that I talk about constantly with my clients, because it changes everything: arousal and desire are not the same thing.


Sex researchers and therapists have drawn a critical distinction between these two states, and conflating them is the source of enormous confusion — both in clinical practice and in how drugs like PT-141 get marketed.


Sexual Arousal


Sexual arousal refers to the physiological response in your body: genital engorgement, lubrication, increased heart rate, skin flushing, heightened sensitivity. It’s the body saying, “Something is happening here.” Arousal can actually occur in the complete absence of desire — a phenomenon researchers call arousal non-concordance (Chivers et al., 2010). Your body can be physiologically aroused by a stimulus even when you have no psychological interest in acting on it whatsoever.


Sexual Desire


Sexual desire, on the other hand, is the psychological motivation — the mental want. It’s the subjective experience of interest, craving, or motivation to engage in sexual activity. Desire is what Rosemary Basson’s influential responsive desire model describes as something that, for many people (and especially many women), doesn’t always come first — it can emerge in response to arousal or intimacy, rather than preceding it (Basson, 2001).


Here’s why this matters for PT-141: the drug appears to primarily target the arousal and desire motivation pathways, but it does so in a brain environment that may have many other competing signals. If the accelerators (biological signals promoting arousal) are turned up but the brakes (stress, pain, anxiety, relationship conflict, fatigue, medication side effects) are also fully engaged, you may not get very far.


Emily Nagoski’s dual control model of sexual response is helpful here: sexual response is the product of both excitatory and inhibitory systems working simultaneously (Nagoski, 2015). PT-141 may rev the accelerator, but it cannot release the brakes.


What Does the Research Actually Say?


The Evidence for Premenopausal Women with HSDD


This is where the evidence is strongest, and it’s still worth reading carefully. Phase 3 clinical trials showed statistically significant but modest improvements in sexual desire and distress compared to placebo in premenopausal women with acquired, generalized HSDD (Kingsberg et al., 2019). The FDA approved it based on this data in 2019.


A 2021 review of the integrated phase 3 data concluded that clinically meaningful responses occurred for some women, with benefits maintained in extension follow-up (Treatment of Hypoactive Sexual Desire Disorder Among Women, 2021). A 2025 systematic review similarly found that bremelanotide improved female desire and arousal outcomes, while emphasizing that benefits across treatments were generally modest (Female Sexual Desire, Arousal, and Orgasmic Dysfunctions, 2025).


The key words in all of this are modest and some women. This is not a drug that turns everyone’s libido to maximum. It is a targeted medication with a specific indication that produces real but limited effects in a specific population.


The Evidence in Men


Man preparing to take a Viagra pill, illustrating conversations about evidence-based treatment options for sexual concerns often discussed in sex therapy and relationship counseling in Orange County.
When it comes to men's sexual health treatments, promising results aren't the same as proven evidence.

For men, the picture is considerably murkier. An older placebo-controlled study in men who did not respond to sildenafil (Viagra) found more positive clinical responses with bremelanotide than placebo, but also reported significantly more drug-related adverse effects and explicitly called for further study before firm conclusions could be drawn (Salvage of Sildenafil Failures with Bremelanotide, 2008). More recent conference data from urology meetings suggest possible benefit for some men, but this falls far short of the completed, peer-reviewed phase 3 program that exists for women (American Urological Association, 2026; Palatin Technologies, 2024).


Bottom line on men: the signal is promising but not definitive. The evidence base is simply not there yet.


The Critics


Not everyone is enthusiastic about the existing evidence even for approved uses. A critical re-analysis of the phase 3 bremelanotide trials argued that while effects are statistically significant, the clinical magnitude may be modest enough that population-level benefit remains unclear (Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder,” 2021). Clinical reviewers also consistently emphasize that side effects are common and long-term safety data remain limited, which is why cautious prescribers restrict use to approved indications (Treatment of Hypoactive Sexual Desire Disorder Among Women, 2021; American Urological Association, 2026).


The Safety Profile: What You Need to Know


I want to give this section significant real estate, because the side effect profile of PT-141 is where things get clinically (and personally) complicated.


Woman experiencing nausea, dizziness, and a headache, illustrating potential medication side effects discussed in evidence-based sex therapy and sexual health counseling in Orange County.
Every treatment has trade-offs, and understanding the side effects is part of making an informed decision.

The Most Common Side Effects


Across clinical development, the most frequently reported adverse effects were:


The nausea rate is particularly important. A 40% incidence in clinical trials is not trivial. In practice, these side effects are a major reason the drug’s real-world usefulness is narrower than its positive trial signal suggests (Safety Profile of Bremelanotide Across the Clinical Development Program, 2021; Novel Emerging Therapies for Erectile Dysfunction, 2020).



My Personal Experience


I tried PT-141 four times. Here is what happened, clinically and honestly.

Yes — I experienced some physiological arousal. There was a tingling sensation, a kind of heightened physical awareness. The drug did something. The arousal accelerator was, to some degree, engaged.


But here’s what else was true during those four attempts: I was exhausted. I have two small children. I was in my luteal phase (the premenstrual phase of my cycle, when progesterone is high and many women’s libido naturally dips). And most significantly — I was nauseated. Significantly nauseated. I took Zofran (ondansetron, a prescription antiemetic) in advance to try to manage it, and it still hit me hard.


Woman recovering after vomiting, illustrating how medication side effects can affect overall well-being and sexual health conversations in evidence-based sex therapy and relationship counseling in Orange County.
Sometimes the side effects tell you as much about a treatment as the benefits do.

Here is the critical clinical point: when all the brakes are on, no amount of arousal juice is going to move the car.


Nausea is one of the most powerful desire-killers in the human body. It is the opposite of the relaxed, present, connected state that allows desire to emerge. So in a darkly ironic twist, the drug designed to increase desire was, in my experience, actively suppressing the psychological conditions necessary for desire to arise. The physical arousal signal was there; the mental want was absolutely not. And without desire, arousal is just... sensation without context.


This is not a failure of the drug per se — it did what it does. It’s a clinical reality about the complexity of sexual response that no single compound can fully navigate.


Who Might Actually Benefit?


Based on the evidence and clinical experience, bremelanotide is best understood as a niche, not a broad-spectrum, therapy.


Premenopausal woman reflecting on sexual well-being and evidence-based treatment options discussed in sex therapy and relationship counseling in Orange County.
The right treatment depends on the right diagnosis—not every low-desire experience has the same solution.

The population most likely to see meaningful benefit:

  • Premenopausal women with a clinical diagnosis of acquired, generalized HSDD (not general low libido or situational desire discrepancy)

  • Women who have no uncontrolled hypertension or cardiovascular contraindications

  • Women who are not highly sensitive to nausea or who tolerate antiemetic pretreatment well

  • Women whose desire difficulties are not primarily context-driven (i.e., not primarily about relationship conflict, stress, fatigue, depression, or adverse life circumstances)


For everyone else — including people with situational desire concerns, people whose libido is affected by relationship dynamics, people in high-stress life phases, or anyone whose “brakes” are on for reasons that a drug cannot address — the evidence does not support PT-141 as a meaningful solution.


And for men, the honest answer is that we simply don’t yet have the evidence to make confident clinical recommendations outside the research setting.



If Not PT-141, Then What?


This is the part I care most about as a therapist, because it redirects from a pharmaceutical shortcut to the deeper work that actually produces lasting change.


Address the Brakes First


Using Emily Nagoski’s dual control model as a framework: if you have significant inhibitory inputs — chronic stress, unresolved relationship conflict, body image concerns, trauma history, hormonal fluctuations, depression, anxiety, medication side effects, sleep deprivation, or parenting exhaustion — addressing those inputs will do far more for your desire than anything you can inject (Nagoski, 2015).


Consider Context-Based Interventions


Research on low desire consistently supports psychological and relational interventions, including mindfulness-based sex therapy, couples therapy, and psychoeducation about responsive desire models, as effective approaches for many people (Brotto & Goldmeier, 2015). Understanding that desire doesn’t have to precede arousal — that for many people, willingness and context create the conditions for desire to emerge — is itself liberating.


Evaluate Hormonal Contributors


For women, particularly those in perimenopause or who have undergone surgical menopause, hormonal evaluation and, where appropriate, evidence-based hormonal therapy may produce meaningful improvements in desire that no melanocortin agonist can replicate (Treatment of Hypoactive Sexual Desire Disorder Among Women, 2021).


Work with a Qualified Clinician


HSDD is a clinical diagnosis that requires thorough evaluation. If you are concerned about low desire, a sex-positive physician, gynecologist, or a sex therapist who collaborates with medical providers is your best starting point — not wellness influencers or peptide clinics operating outside standard care.


Woman meeting with a healthcare provider for a sexual health evaluation, reflecting the collaborative approach between medical care and sex therapy often recommended in Orange County.
The best place to start with low desire is a thorough evaluation—not a quick fix.


The Bottom Line


PT-141 / bremelanotide / Vyleesi is a real, FDA-approved medication with moderate evidence for a specific indication. It is not a broad-spectrum libido booster. It is not magic. And for many people — including, on four attempts, this sex therapist — the side effect profile substantially limits its practical utility.


The most important insight I can offer is this: arousal and desire are different, and no drug can manufacture the psychological, relational, and contextual conditions that desire requires. If your brakes are on — whether that’s nausea, fatigue, stress, resentment toward your partner, postpartum exhaustion, or being in your luteal phase with two kids under five — no amount of melanocortin activation is going to move the needle on your mental want.


Woman feeling nauseous while her partner comforts her, reflecting the importance of addressing both physical and relationship factors through evidence-based sex therapy and couples counseling in Orange County.
Real healing often comes from understanding the whole picture, not just treating the symptom.

That’s not a pessimistic message. It’s actually a hopeful one: it means the solution isn’t in a vial. It’s in addressing the whole, complicated, beautifully human context of your life. And that is exactly the kind of work that sex therapy is designed for.


If this resonated with you, I’d love for you to subscribe to my YouTube channel → where I break down research like this every week in a way that’s actually accessible — and occasionally very honest about my own experiments.


References


 
 
 

Comments

bottom of page